Highest-materiality recent filing
Chairman and CFO resign; Uri Tadelis appointed as new CFO
Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026.
Director Yehuda Eliya term expires, leaves Raphael board effective Dec 31, 2025
Dr. Yehuda Eliya's board term expired Dec 31, 2025; ceased serving as director.
Raphael Pharmaceutical ready to launch RaphaWell RA supplement in US after clinical trial
RaphaWell is a 100% natural, plant-based dietary supplement for rheumatoid arthritis symptom management.
Raphael Pharma board member resigns; Zvi Laufer Laor appointed as director
Dr. Igal Louria Hayon resigned from Board effective Aug 1, 2025; no disagreement; remains CTO.
Raphael Pharmaceuticals appoints Ajay Kumar Dhadha as Director and Chairman, replacing Shlomo Pilo
Board expanded by one seat; Ajay Kumar Dhadha appointed Director and Chairman effective January 8, 2025.
Raphael Pharma reports positive proof-of-concept study of cannabinoid formula in RA
DAS28 score reduced by 19.2%, moving from high to moderate disease activity in 12 patients.
Weinstein International CPA dismissed as independent auditor effective September 5, 2024.
Raphael Pharmaceutical increases authorized common shares to 50M (from 21M)
Authorized common shares increased from 21,020,560 to 50,000,000 effective June 26, 2024.
Raphael Pharma launches US proof-of-concept CBG trial for rheumatoid arthritis
Proof-of-concept clinical trial begun in US for Cannabigerol (CBG) in active Rheumatoid Arthritis patients.
Israeli Ministry of Health approved Raphael Pharmaceutical's application to commence a Phase IIa clinical trial in COVID-19 patients.
Raphael Pharma corrects CTO deal: $9k/month, 999k warrants at $0.01, royalty share
Service agreement with CTO Dr. Igal Louria Hayon corrected, monthly fee $9,000 through Dec 31, 2022.
Raphael Pharmaceutical accepted for OTCQB up-list, to trade under 'RAPH'
Application submitted September 1, 2022; notified of acceptance on October 7, 2022.
Raphael Pharma dismisses Deloitte auditor, Chairman Press resigns; new exec comp agreements
Dismissed Brightman Almagor Zohar (Deloitte) as auditor; appointed Weinstein International as new independent auditor.
Mr. Ajay Kumar Dhadha voluntarily resigned from his positions as Chairman of the Board of Directors and Director of the Company, effective June 30, 2026.
Mr. Guy Ofir voluntarily resigned from his positions as Chief Financial Officer, General Counsel, and Director of the Company, effective July 16, 2026.
Effective July 16, 2026, the Company appointed Mr. Uri Tadelis as its Chief Financial Officer.
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
On June 30, 2022, Prof. Joseph Press informed the Company that he intended to resign from the Board of Directors, effective immediately.
Max materiality 0.70 · Median 0.55 · Most common event other_material